Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease).

Namoglu EC, Hughes ME, Plastaras JP, Landsburg DJ, Maity A, Nasta SD.

Leuk Lymphoma. 2019 Dec 26:1-7. doi: 10.1080/10428194.2019.1703971. [Epub ahead of print]

PMID:
31876204
2.

Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.

Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN, Namoglu E, Nasta SD.

Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):791-798. doi: 10.1016/j.clml.2019.09.612. Epub 2019 Sep 28.

PMID:
31648953
3.

Management of giant cell hepatitis associated with chronic lymphocytic leukemia - a case series and review of the literature.

Rhodes JM, Schuster SJ, Furth EE, Kennard K, Nasta SD, Svoboda J, Porter DL, Mato AR.

Cancer Biol Ther. 2019;20(8):1136-1140. doi: 10.1080/15384047.2019.1598763. Epub 2019 May 15.

PMID:
31091174
4.

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.

Landsburg DJ, Hughes ME, Koike A, Bond D, Maddocks KJ, Guo L, Winter AM, Hill BT, Ondrejka SL, Hsi ED, Nasta SD, Svoboda J, Schuster SJ, Bogusz AM.

Blood Adv. 2019 Jan 22;3(2):132-135. doi: 10.1182/bloodadvances.2018026401. No abstract available.

5.

Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.

Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J.

Oncologist. 2019 Jul;24(7):955-962. doi: 10.1634/theoncologist.2018-0538. Epub 2018 Dec 19.

6.

Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study.

Farhan A, Chong EA, Schuster SJ, Strelec L, Nasta SD, Landsburg D, Svoboda J.

Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):109-115. doi: 10.1016/j.clml.2018.10.001. Epub 2018 Oct 13.

PMID:
30448048
7.

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J.

Cytotherapy. 2018 Dec;20(12):1415-1418. doi: 10.1016/j.jcyt.2018.10.003. Epub 2018 Oct 29.

PMID:
30385043
8.

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS.

Nagle SJ, Shah NN, Ganetsky A, Landsburg DJ, Nasta SD, Mato A, Schuster SJ, Reshef R, Tsai DE, Svoboda J.

Int J Hematol Oncol. 2017 Dec;6(4):113-121. doi: 10.2217/ijh-2017-0020. Epub 2018 Jan 26.

9.

Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.

Cherng HJ, Sargent RL, Nasta SD, Svoboda J, Schuster SJ, Mato AR, Schrank-Hacker A, Morrissette JJD, Landsburg DJ.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):673-678. doi: 10.1016/j.clml.2018.06.012. Epub 2018 Jun 15.

PMID:
30033208
10.

Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ.

Blood. 2018 Sep 6;132(10):1022-1026. doi: 10.1182/blood-2018-03-837609. Epub 2018 Jun 20.

PMID:
29925499
11.

A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.

Gumber R, Cohen JB, Palmer MB, Kobrin SM, Vogl DT, Wasserstein AG, Nasta SD, Bleicher MB, Bloom RD, Dember L, Cohen A, Weiss BM, Hogan JJ.

Kidney Int. 2018 Jul;94(1):199-205. doi: 10.1016/j.kint.2018.02.020. Epub 2018 May 11.

PMID:
29759418
12.

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaac K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS.

Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.

13.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.

N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.

14.

The role of novel immunotherapies in non-Hodgkin lymphoma.

Pishko A, Nasta SD.

Transl Cancer Res. 2017 Feb;6(1):93-103. doi: 10.21037/tcr.2017.01.08.

15.

Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.

Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR, Loren AW, Schuster SJ, Stadtmauer EA, Svoboda J.

Am J Hematol. 2017 Sep;92(9):879-884. doi: 10.1002/ajh.24792. Epub 2017 Jun 9.

16.

Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.

Hatem J, Schrank-Hacker AM, Watt CD, Morrissette JJ, Rubin AI, Kim EJ, Nasta SD, Wasik MA, Bogusz AM.

Diagn Pathol. 2016 Dec 19;11(1):137.

17.

A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.

Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SD.

Cancer. 2017 Apr 15;123(8):1363-1371. doi: 10.1002/cncr.30482. Epub 2016 Dec 16.

18.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

PMID:
27601462
19.

PET/CT in the Evaluation of Relapsed or Refractory Hodgkin Lymphoma.

Jauhari S, Nasta SD.

Am J Hematol Oncol. 2016 Sep;12(9):8-13.

20.

Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.

Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, Loren AW, Frey NV, Stadtmauer EA, Porter DL, Schuster SJ, Nasta SD.

Am J Hematol. 2016 Jul;91(7):672-6. doi: 10.1002/ajh.24372. Epub 2016 Apr 24.

21.

Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.

Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV.

Br J Haematol. 2016 Jul;174(2):332-4. doi: 10.1111/bjh.13771. Epub 2015 Sep 25. No abstract available.

PMID:
26403537
22.

Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.

Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Nasta SD, Loren A, Frey N, Perl A, Cohen AD, Weiss BM, Stadtmauer EA, Vogl DT.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):536-40. doi: 10.1016/j.clml.2015.05.006. Epub 2015 Jun 6.

PMID:
26141214
23.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL.

J Clin Oncol. 2015 Jul 20;33(21):2392-8. doi: 10.1200/JCO.2014.60.1203. Epub 2015 Jun 8.

24.

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.

Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A.

Br J Haematol. 2015 Aug;170(4):504-14. doi: 10.1111/bjh.13463. Epub 2015 Apr 24. Review.

PMID:
25907897
25.

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.

Chong EA, Ahmadi T, Aqui NA, Svoboda J, Nasta SD, Mato AR, Walsh KM, Schuster SJ.

Clin Cancer Res. 2015 Apr 15;21(8):1835-42. doi: 10.1158/1078-0432.CCR-14-2221. Epub 2015 Jan 28.

26.

Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma.

Huntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J.

Leuk Lymphoma. 2015;56(9):2579-84. doi: 10.3109/10428194.2015.1007506. Epub 2015 Feb 11.

PMID:
25629993
27.

The importance of multidisciplinary healthcare for paraneoplastic pemphigus.

Al Zamel G, Micheletti RG, Nasta SD, Palakshappa J, Stoopler ET.

Spec Care Dentist. 2015 May-Jun;35(3):143-7. doi: 10.1111/scd.12093. Epub 2014 Sep 26.

PMID:
25257550
28.

A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein-Barr virus polymerase chain reaction in multiple cancer types.

Tsai DE, Luskin MR, Kremer BE, Chung AK, Arnoldi S, Paralkar VR, Nasta SD, Stadtmauer EA, Schuster SJ, Xavier M.

Leuk Lymphoma. 2015 May;56(5):1530-2. doi: 10.3109/10428194.2014.963577. Epub 2014 Nov 5. No abstract available.

PMID:
25219594
29.

The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.

Nagle SJ, Chong EA, Chekol S, Shah NN, Nasta SD, Glatstein E, Plastaras JP, Torigian DA, Schuster SJ, Svoboda J.

Cancer Med. 2015 Jan;4(1):7-15. doi: 10.1002/cam4.322. Epub 2014 Sep 10.

30.

R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.

Frosch Z, Luskin MR, Landsburg DJ, Schuster SJ, Svoboda J, Loren AW, Porter DL, Stadtmauer EA, Nasta SD.

Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):92-7. doi: 10.1016/j.clml.2014.07.017. Epub 2014 Aug 1.

PMID:
25174772
31.

'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.

Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJ, Schuster SJ.

Br J Haematol. 2014 Aug;166(3):369-74. doi: 10.1111/bjh.12901. Epub 2014 Apr 25.

PMID:
24761809
32.

Could treatment with R-HCVAD/R-MA as compared to R-CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma?

Landsburg DJ, Schuster SJ, Svoboda J, Nasta SD.

Br J Haematol. 2014 Apr;165(1):145-6. doi: 10.1111/bjh.12702. Epub 2013 Dec 19. No abstract available.

PMID:
24354694
33.

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.

Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, Mato AR, Schuster SJ.

Cancer. 2014 Jan 15;120(2):222-8. doi: 10.1002/cncr.28405. Epub 2013 Oct 7.

34.

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.

Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R, Svoboda J.

Am J Hematol. 2013 Oct;88(10):890-4. doi: 10.1002/ajh.23524. Epub 2013 Aug 1.

35.

Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.

Landsburg DJ, Stadtmauer E, Loren A, Goldstein S, Frey N, Nasta SD, Porter DL, Tsai DE, Perl AE, Hexner EO, Luger S.

Am J Hematol. 2013 Aug;88(8):657-60. doi: 10.1002/ajh.23468. Epub 2013 Jun 5.

36.

Outcomes after involved-field radiation therapy (IFRT) with or without rituximab in patients with early-stage low-grade non-Hodgkin lymphoma (NHL) staged with CT and PET.

Lukens JN, Nasta SD, Fram B, Glatstein E, Plastaras JP.

Am J Clin Oncol. 2014 Feb;37(1):35-40. doi: 10.1097/COC.0b013e31826106c9.

PMID:
22992623
37.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL.

N Engl J Med. 2012 Jul 12;367(2):135-45. doi: 10.1056/NEJMoa1201248.

38.

Prediction and Early Detection of Response by NMR Spectroscopy and Imaging.

Lee SC, Arias-Mendoza F, Poptani H, Delikatny EJ, Wasik M, Marzec M, Schuster SJ, Nasta SD, Svoboda J, O'Connor OA, Smith MR, Glickson JD.

PET Clin. 2012 Jan;7(1):119-26. doi: 10.1016/j.cpet.2011.12.007. No abstract available.

39.

Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma.

Stephen S, Morrissey KA, Benoit BM, Kim EJ, Vittorio CC, Nasta SD, Showe LC, Wysocka M, Rook AH.

Am J Hematol. 2012 Feb;87(2):226-8. doi: 10.1002/ajh.22231. Epub 2011 Dec 21.

40.

Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance.

Ahmadi T, McQuade J, Porter D, Frey N, Loren AW, Goldstein SC, Svoboda J, Stadtmauer E, Schuster SJ, Nasta SD.

Bone Marrow Transplant. 2012 Aug;47(8):1082-6. doi: 10.1038/bmt.2011.218. Epub 2011 Nov 14.

PMID:
22080969
41.

Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas.

Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, Goldstein SC, Loren A, Rook AH, Kim EJ, Porter DL.

Bone Marrow Transplant. 2012 Jul;47(7):940-5. doi: 10.1038/bmt.2011.201. Epub 2011 Oct 24.

42.

NMR metabolic and physiological markers of therapeutic response.

Lee SC, Poptani H, Delikatny EJ, Pickup S, Nelson DS, Schuster SJ, Nasta SD, Svoboda J, Goldstein SC, Wallace SG, Loevner LA, Mellon EA, Reddy R, Glickson JD.

Adv Exp Med Biol. 2011;701:129-35. doi: 10.1007/978-1-4419-7756-4_18.

PMID:
21445779
43.

Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.

Olin RL, Kanetsky PA, Ten Have TR, Nasta SD, Schuster SJ, Andreadis C.

Am J Hematol. 2010 Apr;85(4):255-60. doi: 10.1002/ajh.21655.

44.

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM.

Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20.

45.

A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.

Gardner JM, Introcaso CE, Nasta SD, Kim EJ, Vittorio CC, Rook AH.

J Am Acad Dermatol. 2009 Jul;61(1):112-6. doi: 10.1016/j.jaad.2008.11.889.

PMID:
19539845
46.

Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.

Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.

Am J Hematol. 2007 Dec;82(12):1071-5.

47.

Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.

Park M, Liu GT, Piltz-Seymour J, Wisda CL, Rook AH, Junkins-Hopkins JM, Nasta SD, Kim EJ.

Leuk Lymphoma. 2007 Apr;48(4):808-11. No abstract available.

PMID:
17454642
48.

Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literature.

Frey NV, Svoboda J, Andreadis C, Tsai DE, Schuster SJ, Elstrom R, Rubin SC, Nasta SD.

Leuk Lymphoma. 2006 Sep;47(9):1894-901.

PMID:
17065003
49.

Treatment of PTLD with rituximab or chemotherapy.

Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, Tsai DE.

Am J Transplant. 2006 Mar;6(3):569-76.

50.

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.

Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, Tsai DE, Nasta SD, Elstrom RL, Goldstein SC, Downs LH, Mangan PA, Cunningham KA, Hummel KA, Gimotty PA, Siegel DL, Glatstein E, Stadtmauer EA.

Bone Marrow Transplant. 2005 Dec;36(11):955-61.

PMID:
16205727

Supplemental Content

Loading ...
Support Center